Table 1 Characteristics of 97 previous diagnosed de novo acute erythroid/myeloid leukemia patients
Total N = 97 | MDS N = 65 | AML N = 32 | P | |
|---|---|---|---|---|
Characteristics | ||||
Sex, M/F | 60/37 | 46/19 | 14/18 | 0.01 |
Median age, y(range) | 37 (11–75) | 39 (11–70) | 33 (15–75) | 0.044 |
Median hemoglobin level, g/L(range) | 72 (36–141) | 71 (36–141) | 73 (41–119) | 0.615 |
Median WBC, ×109/L(range) | 3.5 (0.61–62.9) | 3.36 (0.61–44.83) | 4.25 (1.21–62.9) | 0.201 |
Median platelet count, ×109/L(range) | 49 (8–480) | 49 (9–480) | 46 (8–233) | 0.441 |
Cytogenetic results, % | ||||
Normal karyotype | 77.8 (70/90) | 76.3 (45/59) | 80.6 (25/31) | 0.635 |
Complex karyotype | 10 (9/90) | 11.9 (7/59) | 6.5 (2/31) | 0.657 |
Monosomy karyotype | 5.6 (5/90) | 5.1 (3/59) | 6.5 (2/31) | 1.0 |
Intermediate MRC category | 87.8 (79/90) | 86.4 (51/59) | 87.5 (28/32) | 1.0 |
Unfavorable MRC category | 12.2 (11/90) | 13.6 (8/59) | 9.4 (3/32) | 0.804 |
Good IPSS category | 78.9 (71/90) | 78.0 (46/59) | 80.6 (25/31) | 0.767 |
Intermediate IPSS category | 10 (9/90) | 10.2 (6/59) | 9.7 (3/31) | 1.0 |
Adverse IPSS category | 11.1 (10/90) | 11.9 (7/59) | 9.7 (3/31) | 1.0 |
Molecular mutations, % | ||||
NPM1 mutation | 19.1 (9/47) | 18.2 (6/33) | 21.4 (3/14) | 1.0 |
FLT3-ITD mutation | 4.3 (3/69) | 6.5 (3/46) | 4.3 (1/23) | 1.0 |
CEBPA single mutation | 6.4 (3/47) | 6.3 (2/32) | 6.7 (1/15) | 0.487 |
CEBPA double mutation | 6.4 (3/47) | 3.1 (1/32) | 13.3 (2/15) | 0.487 |
DNMT3A R882 mutation | 9.1 (3/33) | 11.5 (3/26) | 0 (0/7) | 1.0 |